BEDFORD, Mass., Nov. 17 /PRNewswire/ -- MicroCHIPS, a developer of intelligent implanted devices, has been selected as the inaugural recipient of the 2008 AAPS Drug Delivery Technology Award at the annual meeting of the American Association of Pharmaceutical Scientists in Atlanta. The new award recognizes outstanding research pertaining to novel drug delivery technologies.
John Santini, Jr., PhD, President and CEO of MicroCHIPS, will accept the award and present an overview of MicroCHIPS' innovative technology in a talk titled, "Achieving Protein and Peptide Delivery Through Novel Microreservoir Platforms". MicroCHIPS is developing next-generation drug delivery and biosensing devices to increase therapeutic control and effectiveness for people with diabetes, osteoporosis and other debilitating diseases.
"Many potent therapeutics aren't effective because of hurdles associated with drug delivery," said Dr. Santini. "Microreservoirs, integrated in long-term implants with wireless communications, can address issues of patient compliance, long-term drug stability, and the need for precisely-timed delivery. We are honored that our work has been recognized for its potential to help millions of people with chronic conditions."
"This prize is a tribute to the leading research being done by the team at MicroCHIPS," said Robert Langer, ScD, Institute Professor at the Massachusetts Institute of Technology and a MicroCHIPS co-founder. "The technology they are developing has important applications in clinical areas with significant unmet needs, both for drug delivery and for biosensing."
MicroCHIPS' award-winning research in drug delivery is focused on the development of a long-term implant for osteoporosis therapy. The microreservoir-based device is being developed to conveniently deliver hPTH(1-34) to help build bone, prevent new fractures, and improve quality of life for those who suffer from osteoporosis. Affecting an estimated 75 million people in Europe, the U.S. and Japan, osteoporosis can lead to debilitating fractures and significant morbidity, especially in elderly patients.
MicroCHIPS, Inc. is pioneering intelligent implanted devices designed to improve the health of millions of people with chronic conditions that require careful monitoring and precise therapy. Based on proprietary microreservoir technology first developed at the Massachusetts Institute of Technology, MicroCHIPS' platform incorporates long-term implant technologies and wireless communications, as well as expertise in protein and peptide formulation for challenging delivery conditions. MicroCHIPS' technologies are designed to transform electromechanical medical devices into highly tuned biochemical sensing and therapy systems. www.mchips.com
The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of more than 13,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to health. AAPS offers timely scientific programs, on-going education, information resources, and opportunities for networking and professional development. To learn more about AAPS, please visit www.aapspharmaceutica.com.
CONTACT: Maggie A. Pax, VP Business Development of MicroCHIPS, Inc.,
+1-781-275-1445, ext. 220
Web site: http://www.mchips.com/